Sentiment Trading

Liminatus Pharma Inc. is a pre-clinical-stage biopharmaceutical company pioneering a second-generation CD47 blockade antibody, IBA101, which shows promise in developing more effective and safer cancer therapies.

Liminatus Pharma Inc.’s stock price has experienced significant fluctuations, reaching a 52-week high of $16.44 and a 52-week low of $4.40, amidst a volatile biopharmaceutical sector.